

## NEWSLETTER

### CHEMICAL & PHARMACEUTICAL

20 - 26 April 2026



#### **April Sees Widespread Price Hikes in the Coatings Industry**

In April 2026, the domestic and international coatings industry experienced a widespread wave of price increases. Leading companies initiated price adjustments intensively, with some companies completing two rounds of price hikes within the month. These adjustments covered all categories, including architectural coatings, industrial paints, wood coatings, and waterproofing materials, with the highest increase reaching 25%. **(ChemNet Chemical Headlines)**

#### **Fertilizer Imports and Exports Surge in Volume and Price in Q1 2026**

According to preliminary statistics from China Customs, China's fertilizer import and export trade showed a simultaneous increase in the first quarter of 2026. From January to March 2026, China's cumulative exports of various fertilizers reached 8.162 million tons, a year-on-year increase of 14.1%. On the import side, China imported 5.001 million tons of various fertilizers in the first quarter, a year-on-year increase of 30.5%. **(ChemNet Chemical Headlines)**

#### **Shin-Etsu Chemical Announces Global Silicone Price Increase of Over 10% Starting May 1st**

On April 17th, Shin-Etsu Chemical officially announced a price adjustment notice for its silicone products, deciding to raise prices for all silicone products in the Japanese and global markets by no less than 10% starting May 1st, 2026. The specific increase will vary depending on the product type. Shin-Etsu Chemical stated that this round of price adjustments is mainly due to the impact of the Middle East geopolitical situation. **(ChemNet Chemical Headlines)**

#### **Brain cancer drug cleared for phase III clinical trials**

Brain cancer drug ACT001 has entered Phase III trials after showing 50%+ survival extension in early studies. The drug crosses the blood-brain barrier and combines existing therapies to potentially extend survival by 75%. Developed over 15 years, it's received multiple international designations including FDA rare pediatric disease status. The trial across 50 Chinese hospitals could lead to market approval within 18 months. **(China Daily)**

#### **Shenzhen's biopharma firm signs deal with global leader in cell therapy**

Shenzhen's Pregene Biopharma has signed an exclusive licensing deal with global cell therapy leader Kite Pharma, valued at up to 1.38 billion euro. The partnership will develop in vivo gene editing therapies for cancers, with Pregene retaining rights in China and Kite managing global commercialization. Notably, this collaboration integrates both parties from early research stages, surpassing a traditional license-out model. **(China Daily)**